liquidbiopsysummit

カンファレンスセッションのアジェンダ

近年生体分子医薬の分野が、かつてない盛り上がりを見せています。最新の研究により、体内の複数の組織から放出された循環セルフリー (cf) DNAや細胞外 (ex) RNAを含む生物流体が特定されたほか、高感度で精度の高い次世代シーケンシング (NGS) 技術の急速な進歩により、各種の生体分子が健康体や病体、治療反応のなかで演じる役割の分析も可能になっているのです。しかし、生物流体をベースにしたDNA/RNA分析法には依然として大きな不安があり、液体生検を実用化し、日常の幅広い用途で利用できるようにするためには、こうした不安を解消するための取り組みが必要不可欠です。とはいえ、プロセスや技術の改善が進んでいるため、分子液体生検が未来の個別化医療の柱になる可能性は高まっていると言えます。

1日目 | 2日目 | 3日目 | 講演者

6月22日 (水)



15:45   メインカンファレンスの登録手続き


16:45   パネルディスカッション:がん治療における液体生検の現在および将来の用途

All agree CTCs and ctDNA are prognostic and predictive biomarkers for cancer. However, different approaches for CTCs/ctDNA detection and analysis to identify these tumor cell subpopulations need technical standardization before their clinical validity and biological specificity may be adequately investigated. Join these panelists as they discuss the current challenges and future opportunities for liquid biopsies.

Panelists:
Ellen_BeasleyEllen M. Beasley, Ph.D., Senior Vice President, Product & Services Research & Development, Business & Product Development, Genomic Health, Inc.

Geoff_OttoGeoff Otto, Ph.D., Senior Director, Molecular Biology & Sequencing, Foundation Medicine

Steven_SoperSteven A. Soper, Ph.D., Professor, Biomedical Engineering & Chemistry; Associate Editor, Analyst; Director, Center for BioModular Multiscale Systems, University of North Carolina

Becky_SuttmanRebecca (Becky) Suttmann, MS, Senior Scientific Researcher, Oncology Biomarker Development, Genentech, Inc.

John_WitteJohn S. Witte, Ph.D., Professor and Head, Division of Genetic and Cancer Epidemiology; Associate Director, Institute for Human Genetics; Co-Leader, Cancer Center Program in Cancer Genetics, University of California, San Francisco


 

17:30   展示会ホールでのレセプション、ポスター発表の見学

18:30   1日目終了


1日目 | 2日目 | 3日目 | 講演者

6月23日 (木)

8:00   コーヒー


腫瘍学:臨床研究の段階へと進みつつある液体生検

8:30   主催者代表の開会挨拶

Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute

8:35   議長の開会挨拶

Jamie Platt, Ph.D., MB(ASCP), Vice President, Genomic Solutions, Molecular Pathology Laboratory Network


8:45   基調講演:がんの疾病管理における液体生検

Ellen_BeasleyEllen M. Beasley, Ph.D., Senior Vice President, Product & Services Research & Development, Business & Product Development, Genomic Health, Inc.

Liquid biopsies can be used to monitor tumor dynamics including recurrence, or to profile individual genetic and genomic markers that are informative of treatment options. Together, these complementary approaches provide precision solutions to help manage disease along the patient cancer journey. These also call for different development, analytical and clinical validation strategies, as well as demonstration of clinical utility.


9:30   結腸直腸がんの非侵襲的バイオマーカーとしての循環RNA

Ajay Goel, Ph.D., Investigator/Professor & Director, Center for Gastrointestinal Research; Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center

Noncoding RNAs (ncRNAs) are emerging as important regulators of gene expression in cancer. Overexpression of specific noncoding RNAs (including microRNAs, SnoRNAs, piRNAs and circular RNAs) has been linked to the stepwise disease progression in colorectal cancer (CRC). Given their cancer-specific pattern of expression, remarkable stability and presence in blood and other body fluids, ncRNAs are considered to be highly promising "liquid biopsy" cancer biomarkers. Accumulating evidence firmly supports the existence of unique "ncRNA signatures" that can not only facilitate earlier detection of the tumor, but can also assist in predicting disease recurrence and therapeutic outcome to current treatment regimens.

10:00   液体生検による遺伝情報へのアクセス

Jian-Bing_FanJian-Bing Fan, Ph.D., CEO, AnchorDx Corp.

The molecular liquid biopsies approach provides non-invasive access to genetic information - somatic mutations, epigenetic changes, and differential expression - about the physiological conditions of our body and diseases. With the rapid development of highly sensitive and accurate technologies such as next-generation sequencing, it is now possible to reliably analyze CTCs and circulating nucleic acids in a clinic setting, which opens a valuable avenue for future genetic studies and human disease diagnosis.

10:30   展示会ホールでの休憩、ポスター発表の見学

11:00   NGSベースの臨床ctDNAアッセイの分析的検証

Geoff_OttoGeoff Otto, Ph.D., Senior Director, Molecular Biology & Sequencing, Foundation Medicine

Profiling circulating tumor DNA (ctDNA) for the genomic alterations (GA) driving oncogenesis promises to provide insight into cancer biology, inform therapy selection when conventional biopsies are unobtainable and enable monitoring of response to therapy. A clinical, NGS-based ctDNA assay was developed, highly accurate detection of GA was analytically validated and clinical utility investigated from patient-matched FFPE and blood samples across lung, breast and colon cancer at different disease stages.

11:30   起源となる組織の証拠であるセルフリーDNAのヌクレオソームフットプリント

Andrew_HillAndrew Hill, Graduate Research Fellow, Jay Shendure Laboratory, Genome Sciences, University of Washington

Nucleosome positioning varies across cell types. Some proportion of cell-free DNA (cfDNA) is protected by nucleosomes, which in principle could allow detection of cell types contributing to cfDNA. We infer nucleosome positioning in cfDNA to identify abnormal contributions in pathologies such as cancer. Because this method does not rely on genetic differences between healthy and pathological contributions, it could potentially broaden the scope of cfDNA-based monitoring and diagnostics.

12:00   詳細は後日発表します



12:15   スポンサー提供のプレゼンテーション (講演者を募集しています)

12:30   休憩

12:45   プレゼンテーションを聞きながらの昼食会 (スポンサーを募集しています) または各自で昼食

13:15   休憩


微量の核酸を捕捉、増幅、分析可能なツール

14:00   議長の発言

Ellen M. Beasley, Ph.D., Senior Vice President, Product & Services Research & Development, Business & Product Development, Genomic Health, Inc.

14:05   生物製剤の用途に対応するナノカーボンコーティングされた多孔質陽極酸化アルミナ

Steven_PrawerSteven Prawer, Ph.D., D.Sc., Professor of Physics, School of Physics, University of Melbourne

Here we demonstrate a new broad-range sensor platform for ultrasensitive and selective detection of circulating DNA down to the single-molecule level. The biosensor is based on a chemically functionalized nanoporous diamond-like carbon (DLC)-coated alumina membrane. The few nanometer-thick, yet perfect and continuous DLC coating confers the chemical stability and biocompatibility of the sensor, allowing its direct application in biological conditions.

14:35   Tオリゴ処理されたポリメラーゼ連鎖反応 (TOP-PCR) :体液から微量のDNAフラグメントを増幅するための手堅い手法

Kuo_Ping_ChiuKuo Ping Chiu, Ph.D., Associate Research Fellow, Genomics Research Center, Academia Sinica

We have developed T oligo-primed PCR (TOP-PCR) for comprehensive amplification of minute DNA fragments. TOP-PCR adopts homogeneous adaptor (generated by P oligo and T oligo) for efficient ligation to A-tailed DNA, followed by PCR amplification primed by T oligo. We demonstrate that TOP-PCR maintains the size profile of the DNA sample and is a superior method for recovering minute DNA in body fluids. It maximizes the resolution of Illumina sequencing.

15:05   スポンサー提供のプレゼンテーション (講演者を募集しています)

15:20   展示会ホールでの休憩、ポスター発表の見学

16:00   遺伝子アッセイ開発での試料調製

Toumy Guettouche, Ph.D., Director, Early Development & Genetics Assay Development, Sequencing Unit, Roche Molecular Systems

16:30   液体生検での試料調製

Jamie_PlattJamie Platt, Ph.D., MB(ASCP), Vice President, Genomic Solutions, Molecular Pathology Laboratory Network

The introduction of NGS has enabled some remarkable applications which allow for less invasive specimen acquisition, and improved sensitivity and specificity. Liquid biopsy is one application that holds enormous promise as a tool for monitoring therapeutic response, detect residual disease, and even provide an earlier diagnosis. However, one fact remains: you can't detect what you haven't sampled. The key issues and opportunities for liquid biopsy sample prep will be discussed.

17:00   次世代液体生検:血液の液滴を利用した腫瘍モニタリング

Chen-Hsiung_YehChen-Hsiung Yeh, Ph.D., CSO, Circulogene Theranostics

Circulating cell-free DNA (cfDNA) can provide a global longitudinal picture of tumor heterogeneity. Large sample volume, low yield, and labor intensiveness are major obstacles for clinical application of cfDNA-based testing. Our proprietary cfDNA sample preparation breakthrough enables clinicians to work with a sample volume as small as 20 microliters (via a finger prick), which can further expedite clinical decision-making and identify targeted therapies for eligible patients in a time- and cost-efficient manner.

17:30   2日目終了、ショートコースの登録手続き



1日目 | 2日目 | 3日目 | 講演者

6月24日 (金)

7:30   朝食をとりながらのグループ討論

Chew over breakfast and provocative discussion topics with your peers. These are moderated discussions with brainstorming and interactive problem solving, allowing conference participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic.

Standards of Evidence, Methods and Materials to Accelerate Liquid Biopsy Development and Adoption

Moderator:
Ellen_BeasleyEllen M. Beasley, Ph.D., Senior Vice President, Product & Services Research & Development, Business & Product Development, Genomic Health, Inc.


Use of Systems or Computational Biology to Decipher the Molecular Information that Arises from High-Throughput Liquid Biopsies from the Plasma

Moderator:
Stephen_ChanStephen Y. Chan, M.D., Ph.D., Director, Center for Pulmonary Vascular Biology and Medicine; Associate Professor of Medicine, Department of Medicine, University of Pittsburgh Medical Center

  • What types of biological questions are amenable for a systems biology approach to liquid biopsies?
  • Differentiating the bioinformatic processes of genomic/transcriptomic analysis from higher-order network analysis
  • Can a systems biology analysis of plasma allow for insight into tissue biology?

NGS for Clinical Infectious Disease Diagnostics

Moderator:
Charles_ChiuCharles Chiu, M.D., Ph.D., Associate Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine, University of California, San Francisco


Nanoscience in the Service of Biological Technologies

Moderator:
Steven_PrawerSteven Prawer, Ph.D., D.Sc., Professor of Physics, School of Physics, University of Melbourne


Future of Circulating Tumor Cells (CTC) in Clinical Practice

Moderator:
Siddarth_RawalSiddarth Rawal, M.D., COO, Circulogix Inc.; Clinical Research Associate, Miller School of Medicine, University of Miami

  • An enormous amount of research has been on going in the field of CTC and numerous companies are coming out with CTC capture and analysis platforms. But how useful do clinicians view this data in their day-to-day decision-making?
  • Are the tests at a point where they are robust, reproducible and consistent across laboratories?
  • All CTC assays are currently research use only. What must happen for these tests to be standardized, inexpensive and acceptable to insurance companies to be used as a clinical test?

Additional Breakout Discussion Groups to be Announced


がん以外の分野への展開:さまざまな標的に対応するための取り組み

8:45   議長の冒頭発言

Charles Chiu, M.D., Ph.D., Associate Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine, University of California, San Francisco

8:50   移植医療でのセルフリーDNA

Kiran_KhushKiran K. Khush, M.D., MAS, FACC, Associate Professor, Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine

This talk reviews clinical applications of cell-free DNA testing in the field of solid organ transplantation. Topics covered include (1) monitoring for acute rejection, with illustrative cases from heart and lung transplantation, (2) monitoring of the transplant recipients' virome, and how it changes with introduction and weaning of immunosuppression, and (3) non-biased detection of disease-causing pathogens in transplant recipients.

9:20   抗レトロウィルス療法における患者のHIV潜伏宿主の液体生検

Xiahoe_LiuXiaohe Liu, Ph.D., Senior Scientist & Co-Leader, Rare Cell Technology Program, Biosciences Division, SRI International

A major hurdle in HIV eradication research is the lack of robust assays to characterize the reservoir cells that harbor HIV in the presence of anti-retroviral therapy (ART). We applied FAST (Fiber-optic Array Scanning Technology) to detect and characterize rare cells that express HIV proteins in peripheral blood of patients on ART. Our data suggest that FAST may be a new, important method to identify and measure replication competent proviruses.

9:50   セルフリー流体から感染症を診断するためのメタゲノム次世代シーケンシング

Charles_ChiuCharles Chiu, M.D., Ph.D., Associate Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine, University of California, San Francisco

Metagenomic next-generation sequencing (mNGS) is a powerful approach to the diagnosis of infectious diseases, as it does not rely on targeted primers or probes. A single sequencing test is able to identify all viruses, bacteria, fungi, and parasites in clinical samples. Here we describe implementation of a clinically validated mNGS assay from cerebrospinal fluid to diagnose meningitis and encephalitis in critically ill hospitalized patients.

10:20   スポンサー提供のプレゼンテーション (講演者を募集しています)

10:35   展示会ホールでの休憩、ポスター発表の見学

11:10   血中遊離病原体の検出:液体生検で感染体を検出するための高感度RNAシーケンシングのアプローチ

Andrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

11:40   免疫プロファイルを利用した神経疾患の分類

Nancy_MonsonNancy Monson, Ph.D., Associate Professor, Department of Neurology and Neurotherapeutics & Department of Immunology, University of Texas Southwestern Medical Center

Cerebrospinal fluid (CSF) samples have been a useful tool in the diagnosis of neurological diseases involving the central nervous system (CNS). Our laboratory has focused on finding new ways to use CSF as a diagnostic tool for multiple sclerosis, an autoimmune disease of the CNS. We discovered that antibody genetics of CSF-derived B cells can be used to identify patients who have MS and patients who will develop MS in the future with 84-92% accuracy.

12:10   スポンサー提供のプレゼンテーション (講演者を募集しています)

12:40   休憩

12:45   プレゼンテーションを聞きながらの昼食会 (スポンサーを募集しています) または各自で昼食

13:15   休憩


健康体および病体のなかで細胞外RNAが演じる役割の発見

14:00   議長の発言

Lynne T. Bemis, Ph.D., Chair, Biomedical Sciences, University of Minnesota


14:05   基調講演:バイオマーカーとしての循環細胞外RNA

Muneesh_TewariMuneesh Tewari, M.D., Ph.D., Associate Professor, Internal Medicine and Biomedical Engineering & Ray and Ruth Anderson-Laurence M. Sprague Memorial Research Professor, University of Michigan Health System

MicroRNAs as well as other classes of RNA have been found to be present in blood and other biofluids in extracellular form and are being actively investigated as biomarkers for cancer and many other diseases. I review some of the history of this field, current knowledge about circulating microRNA biochemistry, key considerations and pitfalls to avoid in performing extracellular RNA biomarker studies, as well as the outlook for the future.


14:45   健康体と病体の心臓血管における循環マイクロRNAの生物学

Stephen_ChanStephen Y. Chan, M.D., Ph.D., Director, Center for Pulmonary Vascular Biology and Medicine; Associate Professor of Medicine, Department of Medicine, University of Pittsburgh Medical Center

Plasma-based circulating microRNAs have attracted attention in cardiovascular medicine, relevant for the study of disease states and normal physiology. I describe our recent findings regarding the dynamic regulation and biological actions of circulating microRNAs in aerobic exercise and in pulmonary hypertension. I discuss new technologies to detect and quantify these factors. Finally, I discuss the potential utility of circulating microRNAs as putative cardiovascular biomarkers and/or therapeutic targets.

15:15   スポンサー提供のプレゼンテーション (講演者を募集しています)

15:30   展示会ホール/ポスター発表会場での休憩

16:00   各種生物流体の細胞外RNAプロファイルの比較とバイオマーカー開発での利用

Kendall_Van_Keuren-JensenKendall Van Keuren-Jensen, Ph.D., Associate Professor, Neurogenomics, TGen

Examination of RNA species from several biofluids can provide a range of information about an individual. For example, there are varying amounts of tissue-specific data and exogenous RNA species present among different biofluids. Depending on the type of disease or location of injury, the choice of biofluid may be an important consideration for biomarker development.

16:30   バイオマーカーとしての可能性を有する小型RNAのレパートリーに含まれるtRNAフラグメント

Lynne_BemisLynne T. Bemis, Ph.D., Chair, Biomedical Sciences, University of Minnesota

tRNA fragments are often abundant in high-throughput studies of extracellular RNA. Initially regarded as breakdown products of mature tRNA, and thus of little consequence, they are now being studied for their regulatory function in health and disease. A review of our current understanding of the functions attributed to these fragments will be presented.

17:00   学会閉幕


* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。


Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


Catalog

 

Corporate Sponsor


QIAGEN


Official Publication
Bio-IT-Word_logo


Lead Sponsoring Publications

BioProcess International


GEN-New Logo


Insight Pharma Reports

 Science AAAS


The Scientist



イベントカレンダー
医療機器関連の国際会議